Sort
10,829 grants matching “car t”
May I Help You? An Avatar Health Concierge for HIV-infected African American MSM
$212,482Mark S Dworkin · University Of Illinois At Chicago · R21 · FY2015 · NR
Development of a cellular therapy product with single specificity and improved persistence to prevent immunity to biotherapeutics
$212,212Moanaro Biswas · Indiana University Indianapolis · R21 · FY2023 · HL
Defining Pre-treatment Correlates of Patient GD2 CAR T Cell Exhaustion and Memory Using Multi-Dimensional Immune Profiling
$212,080Sneha Ramakrishna · Stanford University · K08 · FY2023 · CA
Defining Pre-treatment Correlates of Patient GD2 CAR T Cell Exhaustion and Memory Using Multi-Dimensional Immune Profiling
$212,080Sneha Ramakrishna · Stanford University · K08 · FY2022 · CA
Defining Pre-treatment Correlates of Patient GD2 CAR T Cell Exhaustion and Memory Using Multi-Dimensional Immune Profiling
$212,080Sneha Ramakrishna · Stanford University · K08 · FY2024 · CA
Defining Pre-treatment Correlates of Patient GD2 CAR T Cell Exhaustion and Memory Using Multi-Dimensional Immune Profiling
$212,080Sneha Ramakrishna · Stanford University · K08 · FY2025 · CA
Experimentally Validated Mathematical Modeling of Oncolytic Virus Infection
$211,977Wolfgang Michael Korn · University Of California, San Francisco · R01 · FY2009 · CA
Experimentally Validated Mathematical Modeling of Oncolytic Virus Infection
$211,977Wolfgang Michael Korn · University Of California, San Francisco · R01 · FY2008 · CA
Adoptive T Cell Therapy For Non-Hodgkin Lymphoma
$211,970Michael C Jensen · Beckman Research Institute/City Of Hope · P50 · FY2013 · CA
The Pacific Northwest Prostate Cancer SPORE
$211,901Peter S Nelson · Fred Hutchinson Cancer Center · P50 · FY2025 · CA
Treatment of Mal de Debarquement Syndrome (MdDS) by habituation of Velocity Storage.
$211,875Sergei B. Yakushin · Icahn School Of Medicine At Mount Sinai · R21 · FY2021 · DC
Engaging NHPIs and Activating Communities to Take Steps (ENACTS)
$211,833Ka'imi Alohilani Sinclair · Washington State University · U54 · FY2016 · MD
Novel approaches to enrich CAR-T cell Therapy in brain tumors using focused ultrasound
$211,773Paul A Dayton · Univ Of North Carolina Chapel Hill · R21 · FY2025 · CA
Information and Communication Technologies in Collegiate Drug Use Practices
$211,628Gilbert A Quintero · University Of Montana · R15 · FY2009 · DA
Experimentally Validated Mathematical Modeling of Oncolytic Virus Infection
$211,621Wolfgang Michael Korn · University Of California, San Francisco · R01 · FY2007 · CA
Rapid treatment guidance for antibiotic-resistant disease at the point of care
$211,494Tayyaba Hasan · Massachusetts General Hospital · R21 · FY2016 · TW
Integrating human mobility and pathogen genomics to understand dengue dynamics
$211,472Amy Wesolowski · Johns Hopkins University · R21 · FY2021 · AI
Targeting myeloid cells to increase efficacy of immunotherapy against brain tumors.
$211,464Tyler Eugene Miller · Massachusetts General Hospital · K08 · FY2023 · CA
Targeting myeloid cells to increase efficacy of immunotherapy against brain tumors.
$211,464Tyler Eugene Miller · Case Western Reserve University · K08 · FY2024 · CA
Targeting myeloid cells to increase efficacy of immunotherapy against brain tumors.
$211,464Tyler Eugene Miller · Case Western Reserve University · K08 · FY2025 · CA
Differential Neighborhood Organization: A Multi-Level Theory of Crime
$211,440Ross L Matsueda · University Of Washington · · FY2010 · SBE
Metabolic and molecular regulation of myeloid cell functions in brain cancer
$211,285Filippo Veglia · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · NS
The e-Itch Vital Signs: development of a new mobile outcomes measure for clinical trials in patients with chronic itch
$211,272Mary-Margaret Chren · Vanderbilt University Medical Center · R01 · FY2019 · AR
Redirected T Cell Therapy to Cure Invasive Fungal Infections
$211,202Dimitrios P Kontoyiannis · University Of Tx Md Anderson Can Ctr · R21 · FY2017 · AI
Child Endangerment and Traffic Safety
$211,141Tara D Kelley-Baker · Pacific Institute For Res And Evaluation · R21 · FY2013 · AA